



## **Collegium to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference**

December 12, 2017

CANTON, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will be hosting investor meetings at the Guggenheim Securities 5<sup>th</sup> Annual Boston Healthcare Conference on Wednesday, December 13, 2017 at The InterContinental Boston Hotel in Boston, Massachusetts.

### **About Collegium Pharmaceutical, Inc.**

Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx<sup>®</sup> technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

### **About Xtampza ER**

Xtampza<sup>®</sup> ER is Collegium's first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Contact:

Alex Dasalla

[adasalla@collegiumpharma.com](mailto:adasalla@collegiumpharma.com)



Source: Collegium Pharmaceutical, Inc.